South Africas HIV programme, once sustained by US support, is at risk. Without replacement funding, South Africa could see a 38 increase in Aids-related deaths by 2028 and up to 150 000 HIV infections .
With some frontline services collapsing and mobile clinics funded by the US emergency fund, Pepfar, lying idle, its feared many of SAs eight million people living with HIV might forgo their treatment.
The average person with HIV in SA is aged 41, which means treatment access isnt just about survival its about protecting our workforce.
But theres a promising breakthrough: the US Food and Drug Administration has approved the HIV prevention jab, lenacapavir, and it could be registered in SA by early 2026.
Health Minister Aaron Motsoaledi told Health Beat hell find the money to buy the jab if donors cant help. But how much should we pay for it? Find out.
In todays newsletter , our Health Beat team asks Will SA buy the anti-HIV jab lenacapavir?. Sign up for our newsletter today .